Follistatin

Follistatin is a secreted, single-chain glycosylated protein that functions as a high-affinity binding protein for members of the transforming growth factor-β (TGF-β) superfamily. PMID 29020616PMID 9799587 The molecule consists of a 63-residue N-terminal domain followed by three repeating follistatin domains (FSD1, FSD2, and FSD3), each containing 10 cysteine residues. PMID 11279126 Three major isoforms exist (FST288, FST303, and FST315) that differ in their tissue distribution and cell-surface binding properties, with FST288 showing the strongest heparin-binding affinity. PMID 16627583

Follistatin is expressed in various tissues throughout the body, including the liver, ovaries, pituitary gland, skeletal muscle, and reproductive tissues. PMID 29020616PMID 9799587 The protein was first identified in 1987 as a follicle-stimulating hormone (FSH) inhibiting substance in ovarian follicular fluid, though subsequent research has revealed much broader biological roles. PMID 9799587

Follistatin's primary biological function is binding and neutralizing members of the TGF-β superfamily, particularly activin, myostatin, and bone morphogenetic proteins (BMPs). PMID 29020616PMID 30874767 The protein binds these ligands with high affinity, blocking their interaction with cell-surface receptors and thereby preventing downstream signaling. PMID 16482217

The mechanism of action involves follistatin wrapping around the target ligand and physically blocking the type II receptor-binding site. PMID 16482217 For activin specifically, the second follistatin domain (FSD2) mediates the high-affinity interaction, with arginine 192 serving as a key residue that inserts between activin's "fingers". PMID 16482217 Interestingly, myostatin binding depends more heavily on FSD1, demonstrating differential ligand specificity among the follistatin domains. PMID 18535106

Beyond its extracellular antagonism activity, follistatin can also translocate into the nucleus under certain stress conditions to maintain cellular homeostasis through mechanisms independent of its ligand-binding function. PMID 29020616

The biological consequences of follistatin's neutralizing activity include:

• Regulation of skeletal muscle growth by inhibiting myostatin, a negative regulator of muscle mass PMID 21068158PMID 30563942
• Modulation of inflammation and immunity by blocking activin A's pro-inflammatory effects PMID 21353885
• Control of reproductive hormone secretion, particularly FSH from the pituitary PMID 30874767PMID 9799587
• Protection under various stress conditions through neutralization of TGF-β superfamily members PMID 29020616

Cell-surface binding via heparin sulfate proteoglycans is critical for follistatin's biological activity, as it concentrates the protein locally and facilitates irreversible ligand neutralization and lysosomal degradation. PMID 16627583PMID 21353885

Follistatin is considered an exerkine, specifically a contraction-induced hepatokine based on evidence that it is secreted from the liver in response to exercise. PMID 21068158

The key evidence supporting follistatin as an exerkine includes:

• Exercise-induced increases in circulating levels: Plasma follistatin increases markedly during and after exercise in humans, with levels rising up to 7-fold at peak (3 hours into recovery) following 3 hours of bicycle exercise. PMID 21068158 The magnitude of increase appears intensity-dependent, as exhaustive but not moderate-intensity exercise induces significant elevations. PMID 30694975
• Hepatic origin: The liver is identified as the primary source of circulating follistatin during exercise. In humans, arterial-venous measurements across the splanchnic bed demonstrate net release of follistatin from the liver both at rest and during exercise. PMID 26652766 In mice, swimming exercise increases both plasma follistatin levels and hepatic follistatin mRNA and protein expression. PMID 21068158
• No skeletal muscle release: Despite initial hypotheses that exercising muscle might secrete follistatin, arterial-venous difference measurements across the exercising limb showed no net release of follistatin from skeletal muscle. PMID 21068158
• Hormonal regulation during exercise: The exercise-induced increase in hepatic follistatin expression is regulated by glucagon, with the glucagon-to-insulin ratio serving as a key determinant of circulating follistatin levels. PMID 30694975PMID 26652766 Glucagon receptor knockout mice show attenuated exercise-induced increases in follistatin expression. PMID 30694975 Epinephrine also regulates hepatic follistatin at rest but is not required for the exercise response. PMID 30694975
• These findings establish follistatin as a liver-derived endocrine signal released during exercise, introducing new perspectives on muscle-liver cross-talk during physical activity. PMID 21068158

Muscle Disorders and Regeneration: Follistatin shows promise for treating Duchenne muscular dystrophy (DMD) through its ability to antagonize myostatin and activin, negative regulators of muscle growth PMID 35850122. An AAV1-mediated intramuscular gene therapy (rAAV1.CMV.huFollistatin344) is being evaluated in phase 1/2 trials for DMD, with results awaited PMID 35850122. Additionally, engineered follistatin variants demonstrate robust muscle regeneration and improved muscle function in preclinical models of muscle injury and atrophy PMID 21689628PMID 24627466.

Follistatin improves skeletal muscle healing by enhancing muscle regeneration, promoting angiogenesis, and reducing fibrosis PMID 21689628. In transgenic mice overexpressing follistatin, significantly greater myofiber regeneration and less fibrosis formation occurred after skeletal muscle injury compared to wild-type mice PMID 21689628. Systemic administration of engineered follistatin variants increases lean muscle mass and accelerates restoration of myofibers and muscle function after injury PMID 24627466.

Inflammatory and Fibrotic Diseases: Follistatin has anti-inflammatory and antifibrotic properties that make it a therapeutic target for conditions including sepsis, liver fibrosis, acute lung injury, asthma, and ischemia-reperfusion injury PMID 23541927. Activin levels increase in both acute and chronic inflammation, and inhibition of activin action through follistatin can reduce inflammation, damage, fibrosis, and morbidity/mortality in various disease models PMID 23541927PMID 21353885.

Metabolic Disorders: Intravascular follistatin gene delivery improves glycemic control in mouse models of type 2 diabetes by reducing serum activin B concentrations, promoting insulinemia, and maintaining functional pancreatic β-cells PMID 32141144. Follistatin overexpression markedly increases insulin-stimulated glucose uptake and completely normalizes muscle glucose uptake in insulin-resistant diet-induced obese mice PMID 31402604.

Pharmacokinetic Optimization: Native follistatin has rapid heparin-mediated hepatic clearance that limits its therapeutic potential PMID 29752426. Engineered variants with reduced heparin-binding affinity or Fc fusion proteins demonstrate 20- to 100-fold improvements in exposure and antibody-like pharmacokinetic profiles, making them more suitable for therapeutic development PMID 29752426PMID 23249626.